Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ADNP
REST API REST API
Homo sapiens
ADNP is differentially expressed in 274 experiments: 119 organism parts: ovary, heart, ... (117 more);, 204 disease states: normal, breast carcinoma, ... (202 more);, 75 cell types 361 cell lines 40 compound treatments and 71 other conditions.
Synonyms ADNP1, KIAA0784
Orthologs E1C3L1_CHICK (Gallus gallus)   adnp (Danio rerio)   E1BCZ9_BOVIN (Bos taurus)   Adnp (Mus musculus)   ADNP (2 of 2) (Danio rerio)   Adnp (Rattus norvegicus)   adnp (Xenopus laevis)   ADNP (Canis familiaris)   (Compare orthologs)
Gene Ontology Term short-term memory, protein binding, regulation of transcription, DNA-dependent, axon, cytoplasm, intracellular, extracellular space, metal ion binding, negative regulation of synaptic transmission, sequence-specific DNA binding, beta-tubulin binding, peptide binding, nucleus, dendrite, chromatin binding, activation of protein kinase activity, negative regulation of gene expression, copper ion binding, zinc ion binding, negative regulation of neuron apoptosis, neuronal cell body, positive regulation of cGMP biosynthetic process, response to carbohydrate stimulus, positive regulation of neuron projection development, negative regulation of protein binding, neuroprotection, positive regulation of peptidyl-tyrosine phosphorylation, cellular response to extracellular stimulus, positive regulation of axon extension, response to inorganic substance, nitric oxide homeostasis, estrous cycle phase, sequence-specific DNA binding transcription factor activity, regulation of protein ADP-ribosylation, positive regulation of synapse assembly
InterPro Term Znf_C2H2-like, Znf_C2H2, Homeobox
UniProt Accession Q9H2P0, E9PQK8
Search EB-eye ENSG00000101126
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-6573, E-GEOD-3526, E-MTAB-62, E-GEOD-18105, E-GEOD-6236, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-MTAB-62, ... (35 experiments)

Factor Value U/D Experiments
A549
2
E-GEOD-3202, E-GEOD-6013
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MCF-7
2
E-GEOD-19639, E-GEOD-20081
MOLT4
2
E-MTAB-37, E-MTAB-62
T84
2
E-MTAB-37, E-GEOD-1474
PC3
1
2
E-GEOD-5258, E-MEXP-2034, E-GEOD-14464
355 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-3920, E-MEXP-750, E-GEOD-4219, E-GEOD-13909, ... (43 experiments)

Factor Value U/D Experiments
embryonic stem cell
1
2
E-MEXP-930, E-GEOD-2248, E-GEOD-26672
leydig cell
1
E-MTAB-25
testis - leydig cell
1
E-AFMX-5
CD34+CD38-/lowCD19+ cell
1
E-MEXP-1403
T-ALL
1
E-GEOD-19069
adipose tissue-derived stem cell
1
E-MEXP-872
69 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-16363, E-MTAB-62, E-MTAB-680, ... (58 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-37, E-MTAB-62, E-MTAB-57
Classic-KS, HIV-, nodular (late) stage
2
E-MTAB-62, E-MEXP-66
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
glioblastoma
2
E-GEOD-4290, E-MTAB-37
lung adenocarcinoma
2
E-MEXP-231, E-GEOD-2514
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
198 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-15205, E-TABM-782, E-GEOD-5824, E-TABM-868, ... (24 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
baseline propofol
1
E-GEOD-4386
unknown
1
E-GEOD-7307
placebo
1
E-MEXP-1335
dimethyl sulfoxide
1
E-GEOD-5824
control
1
E-GEOD-3284
34 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-21374, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-21138, E-GEOD-21887, E-GEOD-19665, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (7 experiments)

Genotype
studied in E-GEOD-17476, E-GEOD-21750, E-MEXP-1235, E-TABM-868, E-TABM-601, ... (8 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-MEXP-2657, E-TABM-127, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-302, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-1926, E-MEXP-2069, E-MEXP-1648, ... (32 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980 ... (5 experiments)

Injury
studied in E-GEOD-19743

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, E-MEXP-1403 ... (5 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-1315, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, E-GEOD-15799, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-6532, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.394 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM